2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs)

BCSCP Board Certified Sterile Compounding Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, USP Standards & CSP Categories

1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions

2 Chapter 2: Facilities, Engineering Controls & Cleaning

2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures

3 Chapter 3: Environmental Monitoring & Facility Certification

3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols

4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique

4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity

5 Chapter 5: Beyond-Use Dating, Storage & Container Rules

5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules

6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding

6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)

7 Chapter 7: Materials, Equipment & Compounding Workflow

7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs

8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility

8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics

9 Chapter 9: Therapeutics, Administration & Patient Monitoring

9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations

10 Chapter 10: Quality Management, Records & Personnel Competency

10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence

11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain

11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA

12 Chapter 12: Safety Management, Investigations, Recalls & Waste

12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management

2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs)

Key Takeaways Explain This Topic AI

A Segregated Compounding Area (SCA) is a designated unclassified space with a defined perimeter that houses an ISO Class 5 PEC for Category 1 CSP compounding only.

CSPs compounded in an SCA or C-SCA are restricted to maximum beyond-use dates of ≤ 12 \le 12 ≤ 12 hours at room temperature or ≤ 24 \le 24 ≤ 24 hours refrigerated; freezing is prohibited.

A sink serving an SCA must be at least 1 meter from the PEC and may be inside the SCA or close to it.

A Containment SCA (C-SCA) for hazardous drug compounding must have fixed walls, negative pressure of 0.01 to 0.03 inch water column relative to all adjacent areas, at least 12 ACPH, and external venting.

Last updated: September 2026

Concept and Role of the Segregated Compounding Area

Not every healthcare setting—such as satellite clinic pharmacies, ambulatory surgical centers, rural critical access hospitals, or oncology infusion suites—possesses the physical footprint or capital resources to construct a full ISO Class 7 cleanroom suite. To accommodate these practice sites, USP General Chapter <797> permits the placement of an ISO Class 5 Primary Engineering Control inside an unclassified space designated as a Segregated Compounding Area (SCA) .

Strict Operational Trade-Off: Category 1 Beyond-Use Dates

Because the air surrounding the PEC in an SCA is unclassified (containing millions of particles and variable microbial bioburden per cubic meter), transient turbulence from walking personnel can occasionally compromise the cabinet's air barrier. Consequently, all preparations compounded in an SCA are classified as Category 1 CSPs :

Controlled Room Temperature : Maximum BUD of 12 hours .

Refrigerated Storage ( 2 ∘ C 2^\circ\text{C} 2 ∘ C to 8 ∘ C 8^\circ\text{C} 8 ∘ C ) : Maximum BUD of 24 hours .

Frozen Storage : PROHIBITED . Category 1 CSPs cannot be frozen to extend their BUD.

SCA Facility Requirements (Non-Hazardous)

An SCA used for non-hazardous sterile compounding must meet strict structural criteria:

Defined Perimeter : The SCA must be a designated space with defined physical boundaries (walls and doors) or a visibly demarcated perimeter.

No Unsealed Exterior Penetrations : The SCA must not contain unsealed windows or doors opening directly to the building exterior.

Proximity Restrictions : The SCA must be located away from high-traffic hospital corridors, construction, restrooms, warehouse receiving bays, and cafeteria food preparation areas.

Plumbing Proximity : The hand-washing sink must be at least 1 meter (about 3.3 feet) from the PEC. It may be either inside the SCA or in close proximity to it.

Containment Segregated Compounding Areas (C-SCAs) under USP <800>

When a facility compounds sterile hazardous drugs (such as antineoplastic chemotherapy agents) without a full cleanroom suite, it must construct a Containment Segregated Compounding Area (C-SCA) under USP <800> .

Mandatory Engineering Specifications for C-SCAs

Unlike non-hazardous SCAs (which can be open areas with marked perimeters), a C-SCA must meet rigid containment mandates:

Fixed Physical Walls and Doors : A C-SCA must be a fully enclosed room separated from surrounding areas by full-height walls and self-closing doors.

Negative Air Pressure : The C-SCA must maintain continuous negative pressure relative to all adjacent unclassified spaces of -0.010 to -0.030 inches of water column ( − 2.5 Pa -2.5\,\text{Pa} − 2.5 Pa to − 7.5 Pa -7.5\,\text{Pa} − 7.5 Pa ) to prevent hazardous vapors from leaking into surrounding clinic spaces.

Air Exchange Rate : Must provide a minimum of 12 Air Changes Per Hour (ACPH) .

External Venting : The C-SCA must be externally vented, and the C-PEC used for sterile HDs (Class II BSC or CACI) must also be externally vented.

Sink Distance : The hand-washing sink must be at least 1 meter from the C-PEC and may be either inside the C-SCA or directly outside it.

Feature Non-Hazardous SCA Hazardous C-SCA
Enclosure Type Room or marked perimeter Enclosed room with fixed walls/doors

Pressure Differential Neutral or ambient Negative: -0.01 to -0.03 inches w.c.

Air Changes Per Hour No minimum specified ≥ 12 \ge 12 ≥ 12 ACPH
Exhaust Mechanism Ambient room return 100% externally vented to outside
Allowable CSP Category Category 1 only (12h RT / 24h cold) Category 1 only (12h RT / 24h cold)
Master Comparative Architecture: Non-Hazardous SCA vs. C-SCA vs. Cleanroom Suite

Engineering Dimension Non-Hazardous SCA Hazardous C-SCA Full Cleanroom Suite (Category 2/3)

Physical Boundary Dedicated room or marked floor perimeter Enclosed room with fixed walls & self-closing doors Multi-room suite (Buffer room + Ante-room)

Room Air Cleanliness Unclassified ambient air Unclassified ambient air ISO Class 7 Buffer + ISO Class 7/8 Ante

Differential Pressure No pressure requirement Continuous negative: − 0.010 to − 0.030 in. w.c. -0.010\text{ to }-0.030\text{ in. w.c.} − 0.010 to − 0.030 in. w.c. Positive ≥ + 0.020 in. w.c. \ge +0.020\text{ in. w.c.} ≥ + 0.020 in. w.c. (or negative for HD)

Air Changes Per Hour No minimum mandated ≥ 12 \ge 12 ≥ 12 ACPH ≥ 30 \ge 30 ≥ 30 ACPH in buffer; ≥ 20 – 30 \ge 20\text{--}30 ≥ 20 – 30 ACPH in ante

Exhaust Destination Ambient room return 100% externally vented to exterior Externally vented (HD) or HEPA recirculated (non-HD)

Primary Control (PEC) ISO Class 5 (HLAFW, VLAFW, CAI) ISO Class 5 (Class II BSC, CACI) ISO Class 5 (LAFW, BSC, CAI, CACI)

Allowable CSP Tier Category 1 CSPs only Category 1 CSPs only Category 2 or Category 3 CSPs
Max Room Temp BUD 12 hours 12 hours Up to 45 days (Category 2) or 90 days (Category 3)
Max Refrigerated BUD 24 hours 24 hours Up to 60 days (Category 2) or 120 days (Category 3)
Frozen Storage Allowed? NO (Prohibited) NO (Prohibited) YES (up to 90 days Category 2; 180 days Category 3)
Operational Decision Workflow and Category 1 Quality Management

Operating an SCA or C-SCA requires rigorous scheduling to avoid administering expired preparations. Pharmacists must integrate compounding schedules with nursing infusion times:

Just-In-Time Compounding: Category 1 CSPs should be compounded close to administration. The BUD marks the time after which a CSP must not be used, stored or transported. Many facilities therefore time preparation so that even a long infusion (for example, one running 6 hours) finishes before the 12-hour room-temperature limit.

Labeling Precision: Labels on Category 1 CSPs must clearly display both the date and the exact hour and minute of expiration (e.g., 'Discard after: 2026-09-29 at 18:30').

Environmental Monitoring: USP <797> sampling targets classified air, which in an SCA means the ISO Class 5 PEC. That requires viable air sampling at least every 6 months and surface sampling at least monthly. The Table 10 cleaning frequencies apply to every surface inside the SCA perimeter except the ceiling, which is cleaned when visibly soiled or when contamination is known or suspected.